# Supplementary Information for

## A hydrophilic three side-chained triazatruxene as a new strong and selective Gquadruplex ligand

Luca Ginnari-Satriani, Valentina Casagrande, Armandodoriano Bianco, Giancarlo Ortaggi, Marco Franceschin<sup>\*</sup>

Dipartimento di Chimica, Università di Roma "La Sapienza", Piazzale A. Moro 5, 00185 Roma, Italy. \*e-mail: marco.franceschin@uniroma1.it

# Organic & Biomolecular Chemistry


#### I. Materials and instrumentation:

2-indolinone and 1,4-diiodobutane were purchased from Fluka; the other commercial reagents and solvents were purchased from Aldrich. TLC glass plates (silica gel 60 F<sub>254</sub>) and silica gel 60 (0.040-0.063 mm) were purchased from Merck. <sup>1</sup>H and <sup>13</sup>C-NMR spectra were performed with Varian Gemini 200 and Varian Mercury 300 instruments. Elemental analyses (C, H, N) were carried out on EA1110 CHNS-O (CE instruments). UV/Vis absorbition spectra were performed on a JASCO V-530 spectrophotometer. MES-KCl buffer is composed by 10 mM MES at pH 6.5 and 50 mM KCl. Single-stranded oligonucleotides were purchased from Eurofins MWG Operon (Ebersberg, sequences are as follows: TG<sub>4</sub>T (5'-TGGGGT-3'); F21T (5'-Germany). Their GGGTTAGGGTTAGGGTTAGGG-3'); DK66 (5'-CGCGAATTCGCG-3'). Calf thymus DNA, used in competition experiments, was purchased from Sigma-Aldrich and subjected to sonication (Sonyprep 150 sonicator) for 8 minutes to obtain an average length of 500bp (according to gel electrophoresis analysis with Mass Ruler DNA ladder mix-low range).

#### **II. Molecular modelling simulations:**

Molecular modelling simulations were performed using the InsightII package and the X-ray structure of the 22-mer human telomeric DNA sequence AGGG(TTAGGG)3 (PDB code 1KF1).<sup>25</sup> The binding site was defined as the external 3' G-quartet plane.<sup>8</sup> Initially 200 ligand orientations were randomly centred on the G-quadruplex structure, charges were not considered and the complexes were minimized for 500 steps. The 75 lowest energy structures were then subjected to simulated annealing, then 500 steps of minimization was followed by molecular dynamics over a period of 10 ps. The resulting structures were then minimized.

#### **III. Detailed scheme for the preparation of AZATRUX:**




**10,15-dihydro-5H-diindolo[3,2-a:3',2'-c]carbazole (2):** A mixture of 2-indolinone **1** (2.0 g, 15 mmol) and 10 ml of POCl<sub>3</sub> was heated at 100°C for 8 h. Then, the reaction mixture was poured into ice and neutralized carefully with KOH until pH 7-8. After neutralization, the precipitate was filtered to give the crude product as a brown solid. The latter was dissolved in methanol, adsorbed on silica gel and purified by flash chromatography (ethyl acetate/n-hexane = 15:85) to give the pure compound of formula **2** as a pale yellow solid (830 mg, yield 48%).


<sup>1</sup>H NMR (200 MHz, acetone-d6) δ 11.08 (1s, 3H, N<sub>arom</sub>-H), 8.52 (1d, 3H, J=7, aromatic H), 7.68 (1d, 3H, J= 7.4, aromatic H), 7.31 (1m, 6H, aromatic H) ppm; <sup>13</sup>C NMR (acetone-d6) δ: 141.0, 136.4, 124.8, 124.5, 121.5, 121.4, 112.9, 103.3 (8 aromatic C) ppm; UV (DMSO)  $\lambda$  max, nm ( $\epsilon$  x10<sup>-4</sup>, M<sup>-1</sup>cm<sup>-1</sup>) : 274 (3.3), 309 (6.8), 325 (3.6) , 342 (1.5); MS (ESI) m/z 344.01 [(M-H)<sup>-</sup>] (Calcd for C<sub>24</sub>H<sub>14</sub>N<sub>3</sub>: 344.40).


5,10,15-tris[4(1-piperidino)butyl]diindolo[3,2-a;3',2'-c]carbazole (3, AZATRUX): A mixture of 2 (355 mg, 1.03 mmol) and KOH (576 mg, 10.3 mmol) in THF (20 ml) was heated under reflux for 10 min. 1,4-Diiodobutane (2.0 ml, 15 mmol) was then added and the mixture was heated under reflux for 6h. The mixture was diluted with AcOEt, washed with 10% aqueous HCl and then with brine solution. The organic layer was dried with  $Na_2SO_4$  and evaporated under vacuum. The crude product was dissolved in chloroform, adsorbed on silica gel and purified by flash chromatography (ethyl acetate/n-hexane = 5:95) to give 5,10,15-tris(4-iodobutyl)diindolo[3,2-a:3',2'-c]carbazole (4, 373 mg, yield 40%) as a dark yellow viscous oil. A mixture of this intermediate compound (209 mg, 0.23 mmol) and piperidine (0.69 ml, 7.0 mmol) was heated in THF (5ml) under reflux for 2h. The mixture was evaporated under reduced pressure and purified by flash chromatography (ethyl acetate saturated with 30% aqueous ammonia solution) to give the compound of formula 3 (161 mg, yield 91%) as a dark yellow viscous oil. The compound 3 (110 mg) was precipitated in the form of its hydrochloride salt by dissolving it in a mixture of methanol/HCl (methanol/aqueous HCl 37%=95:5) and adding diethyl ether: 81 mg of a white solid was obtained with a yield of 58%. <sup>1</sup>H NMR (300 MHz, D<sub>2</sub>O) δ 7.61 (d, 3H, J=7.8, aromatic H), 7.40 (m, 6H, aromatic H), 7.25 (m, 3H, aromatic H), 3.98 (m, 6H, Narom-CH2), 2.89 (br, 6H, Npiperidine-CH2), 2.53 (m, 6H, Npiperidine-CH2), 2.29 (br, 6H, N<sub>piperidine</sub>-CH<sub>2</sub>), 1.49 (1m, 24H, 9N<sub>piperidine</sub>CH<sub>2</sub>-CH<sub>2</sub>, 3N<sub>arom</sub>CH<sub>2</sub>-CH<sub>2</sub>), 1.06 (1m, 6H, CH<sub>2piperidine</sub>) ppm; UV (aq. MES-KCl) λ max, nm (ε x 10<sup>-4</sup>, M<sup>-1</sup>cm<sup>-1</sup>): 255 (2.6), 313 (4.8); HR-MS (ESI) m/z 763.5393 [(M+H)<sup>+</sup>] (Calcd for C<sub>51</sub>H<sub>67</sub>N<sub>6</sub>: 763.5427). Anal. found C 63.5%, H 8.3%, N 8.4%; (Calcd for [C<sub>51</sub>H<sub>66</sub>N<sub>6</sub>·3HCl·5H<sub>2</sub>O]: C63.6 %, H8.3%, N 8.7%).


**5,10,15-tris**(**4-iodobutyl**)**diindolo**[**3,2-a:3',2'-c**]**carbazole** (**4**): <sup>1</sup>H NMR (200 MHz, acetone-d6)  $\delta$  8.30 (1d, 3H, J= 7.8, aromatic H), 7.79 (1d, 3H, J=7.8, aromatic H), 7.38 (1m, 6H, aromatic H), 5.03 (1t, 6H, J=7.4, N<sub>arom</sub>-CH<sub>2</sub>), 3.07 (1t, 6H, J= 7.0, I-CH<sub>2</sub>), 1.89 (1 m, 6H, N<sub>arom</sub>CH<sub>2</sub>-CH<sub>2</sub>), 1.61 (1m, 6H, ICH<sub>2</sub>-CH<sub>2</sub>) ppm; <sup>13</sup>C NMR (acetone-d6)  $\delta$ : 141.4, 138.8, 123.5, 123.3, 121.8, 120.3, 111.3, 103.6 (8 aromatic C), 45.7, 30.6, 30.4, 6.1 (4 C) ppm, MS (ESI) m/z 892.43 [(M+H)<sup>+</sup>] (Calcd for C<sub>36</sub>H<sub>37</sub> I<sub>3</sub>N<sub>3</sub>: 892.43).

**5,10,15-tris**[**4**(**1-piperidino**)**buty**]**diindolo**[**3,2-a:3',2'-c**]**carbazole** (**3**): <sup>1</sup>H NMR (200 MHz, chloroform-d) δ 8.26 (d, 3H, J=8.4, aromatic H), 7.68 (d, 3H, J=8.2, aromatic H), 7.39 (m, 6H, aromatic H), 4.95 (t, 6H, J=7.4, N<sub>arom</sub>-CH<sub>2</sub>), 2.25 (m, 18H, N<sub>piperidine</sub>-CH<sub>2</sub>), 1.99 (m, 6H, N<sub>arom</sub>CH<sub>2</sub>-CH<sub>2</sub>), 1.51 (m, 18H, N<sub>piperidine</sub>CH<sub>2</sub>-CH<sub>2</sub>), 1.39 (m, 6H, CH<sub>2piperidine</sub>) ppm; <sup>13</sup>C NMR (chloroform-d) δ: 140.8, 138.6, 123.2, 122.7, 121.3, 119.7, 110.6, 103.0 (8 aromatic C), 58.2, 54.2, 46.5, 27.5, 25.5, 24.1, 23.4 ppm; UV (DMSO)  $\lambda$  max, nm (ε x10<sup>-4</sup>, M<sup>-1</sup>cm<sup>-1</sup>): 267 (1.9), 318 (6.1), 354 (1.0).












7








**Figure S1:** <sup>1</sup>H-NMR spectrum of AZATRUX as a hydrochloride in D<sub>2</sub>O.

# IV. Evaluation of the binding to quadruplex and duplex DNA by electrospray ionization mass spectrometry (ESI-MS):

ESI-MS spectra were recorded on a Micromass Q-TOF MICRO spectrometer (now Waters) in the negative ionization mode. The rate of sample infusion into the mass spectrometer was 10  $\mu$ l/min and the capillary voltage was set to -2.6 kV. The source temperature was adjusted to 70°C, the cone voltage to 30 V and the collision energy to 5V. Full scan MS spectra were recorded in the m/z range between 800 and 2500, with 100 acquisitions per spectrum. Data were analyzed using the MassLynx software developed by Waters. Samples preparation (in 150 mM ammonium acetate buffer) and evaluation of the binding constants and percentage of bound DNA have been carried out according to the protocol described in a previous paper.<sup>24</sup>



**Figure S2:** ESI mass spectra of  $(TG_4T)_4$  in the presence of AZATRUX at 1:1 molar ratio (a) and of DK66 in the presence of AZATRUX at 1:4 molar ratio (b). Arrows indicate the peaks corresponding to the oligos alone and to the relative 1:1 or 2:1 drug/DNA complexes, in different charge states.

	[CT] = 0	[Gq]:[CT] 1:1	[Gq]:[CT] 1:5
F21T	46	39	14
(TG <sub>4</sub> T) <sub>4</sub>	75	64	44

#### Competition experiments on F21T and (TG<sub>4</sub>T)<sub>4</sub> oligos.


**Table S1:** Values of the percentage of bound quadruplex DNA for samples containing a fixed amount of both drug and G-quadruplex DNA (5  $\mu$ M, 1:1 ratio) and different amounts of calf thymus DNA (CT), at the indicated quadruplex/duplex ratios (in phosphate ions). All values should be considered with an error estimated on at least three independent experiments of about  $\pm 5\%$ .


	[CT] = 0	[Gq]:[CT] 1:1	[Gq]:[CT] 1:5
F21T	1	0.85	0.30
(TG <sub>4</sub> T) <sub>4</sub>	1	0.85	0.59

**Table S2:** Values of normalized percentage bound quadruplex (N%) are elaborated starting from the percentages reported in Table S1 using the following equation:

%quadruplex bound in presence of CT


%quadruplex bound in absence of CT





#### V. Titrations by UV spectroscopy:

F21T was annealed in MES/KCl buffer, heating the sample at 90°C for ten minutes and cooling slowly to room temperature. Both F21T and sonicated CT DNA were diluted in MES/KCl buffer at an initial concentration of 200 $\mu$ M (R=20). Adding increasing volumes of 10 $\mu$ M drug stock the DNA/drug ratio (R) was decreased until a final DNA concentration of 1 $\mu$ M (R=0.1), while taking constant drug concentration. Two series of measures were performed for each DNA to confirm reproducibility.



**Figure S4:** Normalized molar extinction coefficient ( $\epsilon$ N) versus DNA/drug concentration ratio of AZATRUX (10 $\mu$ M) at 313nm with F21T oligo ( $\Box$ , red) and CT DNA ( $\bullet$ , blue).

### VI. In vitro antitumor activity:

Developmental Therapeutics Program		NSC: 749678/1	Conc: 1.00E-5 Molar	Test Date: Feb 02, 2009
One Dose Mean Graph		Experiment ID: 09	020852	Report Date: Mar 03, 2009
Panel/Cell Line	Growth Percent	Mean Growt	h Percent - Growth Pe	rcent
Leukemia CCRF-CEM HL-60(TB) K-562 MOLT-4 RPMI-8226 SR Non-Small Cell Lung Cancer A549/ATCC EKVX HOP-62 HOP-92 NCI-H226 NCI-H226 NCI-H223 NCI-H220 NCI-H220 NCI-H260	-70.40 -77.41 -81.77 -80.62 -49.39 -69.71 -65.99 -91.43 -90.93 -61.09 -86.36 -85.71			
NCI-H460 NCI-H522 Colon Cancer COLO 205 HCC-2998 HCT-116 HCT-15 HT29 KM12 SW-620 CNS Cancer SF-268	-89.96 -49.95 -86.17 -88.55 -97.13 -68.43 -92.47 -80.96 -77.07 -81.71			
SF-295 SF-539 SNB-19 SNB-75 U251 Melanoma	-70.08 -98.69 -94.44 -97.40 -68.42		Ē	
LOX IMVI MALME-3M M14 MDA-MB-435 SK-MEL-2 SK-MEL-28 SK-MEL-5 UACC-257 UACC-62 Ovarian Cancer	-59.18 -76.74 -92.10 -78.66 -68.99 -91.08 -96.57 -56.53 -75.77			
IGROV1 OVCAR-3 OVCAR-4 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-OV-3 Renal Cancer	-31.44 -86.23 -91.26 -91.06 -57.38 -86.02 -98.76			
786-0 A 498 A CHN CAKI-1 RXF 393 SN12C TK-10 UO-31 Prostate Cancer	-92.64 -95.24 -86.31 -81.49 -54.47 -86.45 -81.77 -72.56			
PC-3 DU-145 Breast Cancer MCF7 MDA-MB-231/ATCC HS 578T BT-549 T-47D MDA-MB-468	-93.20 -95.21 -91.99 -80.63 -48.01 -75.72 -68.05 -93.02		_	
Mean Delta Range	-78.94 19.82 67.32			
	150	100 50	) 0 -5	0 -100 -150

**Figure S5:** Growth percent of the indicated cell lines after 48 hours of incubation with 10µM AZATRUX solution, with respect to no-drug control, as reported by a preliminary study at the National Cancer Institute (NIH, Bethesda, MD, USA) over 60 cell lines.<sup>29</sup>